| Title: | Carriage of rare APOB variants predisposes to severe steatotic liver disease and hepatocellular carcinoma |
| Journal: | Journal of Clinical Investigation |
| Published: | 10 Feb 2026 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/41665936/ |
| DOI: | https://doi.org/10.1172/jci201762 |
| URL: | http://www.jci.org/articles/view/201762/files/pdf |
Publication 18314
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
BACKGROUNDMetabolic dysfunction-associated steatotic liver disease (MASLD) has a substantial inherited component. Rare variants in apolipoprotein B gene (APOB) have been implicated in susceptibility to liver steatosis, but their role in disease progression and outcomes is unclear.METHODSWe investigated APOB rare variants in a case-control cohort of people with advanced MASLD versus healthy controls (n = 510 and 261, respectively), a family-based study (n = 43 and literature meta-analysis), the Million Veteran Program (MVP) cohort (n = 94,885), and the UK Biobank (UKBB) (n = 417,657).RESULTSIn the clinical cohort, APOB variants were enriched in people with advanced MASLD (OR 13.8, 95% CI: 2.7-70.7, P = 0.002) and associated with lower circulating lipids, but higher MASLD activity and fibrosis (P < 0.05). In the family study, APOB variants segregated with hepatic steatosis and fibrosis (P < 0.05). Cross-ancestry meta-analysis of the study cohorts yielded pooled ORs for cirrhosis and hepatocellular carcinoma (HCC) of 1.82, 95% CI: 1.33-2.49 and 3.53, 95% CI: 2.09-5.98, respectively. Variants affecting specifically ApoB100 had a 3-fold greater effect on hepatic lipid metabolism compared with those impairing also ApoB48 and were specifically protective against coronary artery disease (P < 0.05). The variants affected cirrhosis risk similarly, but ApoB48/100 had a larger effect on HCC (P < 0.05).CONCLUSIONSRare APOB variants predispose individuals to advanced MASLD and HCC, with distinct contributions from disrupted VLDL and chylomicrons secretion. These findings highlight the interplay between hepatic and intestinal lipid handling, suggesting that APOB genotyping may enhance MASLD risk stratification and patient identification.FUNDINGEuropean Union, Italian Ministry of Health, Swedish Research Council, Veterans Health Administration, NIH.</p>
13 Keywords
- Adult
- Aged
- Apolipoprotein B-100
- Apolipoproteins B
- Carcinoma, Hepatocellular
- Case-Control Studies
- Fatty Liver
- Female
- Genetic Predisposition to Disease
- Humans
- Liver Neoplasms
- Male
- Middle Aged
35 Authors
- Matteo Mureddu
- Serena Pelusi
- Oveis Jamialahmadi
- Marijana Vujkovic
- Lorenzo Miano
- Hadi Eidgah Torghabehei
- Luisa Ronzoni
- Francesco Malvestiti
- Marco Saracino
- Giulia Periti
- Vittoria Moretti
- Craig C. Teerlink
- Julie A. Lynch
- Philip S. Tsao
- Josephine P. Johnson
- Vincenzo La Mura
- Robertino Dilena
- Saleh A. Alqahtani
- Alessandro Cherubini
- EPIDEMIC Study Investigators
- Million Veteran Program
- Francesco Paolo Russo
- Roberta D'Ambrosio
- Mirella Fraquelli
- Salvatore Petta
- Luca Miele
- Umberto Vespasiani-Gentilucci
- Elisabetta Bugianesi
- Rosellina M. Mancina
- Paolo Parini
- Daniele Prati
- Kyong-Mi Chang
- Carolin V. Schneider
- Stefano Romeo
- Luca VC Valenti
1 Application
| Application ID | Title |
|---|---|
| 37142 | UNDERSTANDING THE GENETIC ARCHITECTURE OF CHRONIC LIVER DISEASE |
Enabling scientific discoveries that improve human health